Other novel biomarkers were developed to evaluate kidney damage that, according to Ráduly et al. (2021), are defined as “parameters of physiological, chemical, structural, and genetic changes that show the severity, progress, or presence of histological alteration.” Among those biomarkers are effect biomarkers, including N-acetyl-β-D-glucosaminidase (NAG), Kidney injury molecule-1 (KIM-1), and NGAL, which are excreted in urine because of tubular injury [36]. This evidence concerns the gene LCN2 and Nephropathy.